-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
Author: Shi Bei
On December 21, AstraZeneca announced that it had acquired a supplementary license application (sBLA) for the complement C5 inhibitor Ultomiris (ravulizumab-cwvz), a leading company on the complement track, for the treatment of adult systemic myasthenia gravis (gMG).
gMG is a rare and debilitating chronic autoimmune neuromuscular disease that can cause loss of muscle function and severe weakness
Ultomiris is the first and only approved long-acting C5 complement inhibitor with immediate, complete and continuous complement inhibition
This marketing application is based on the results of a phase III clinical study of Ultomiris in the treatment of gMG patients
Ultomiris and Soliris are the two most important listed products obtained by AZ in acquiring Alexion for US$39 billion
On August 20th, AstraZeneca announced that the Phase III CHAMPION-ALS study of Ultomiris in the treatment of adult amyotrophic lateral sclerosis (ALS) was evaluated by the Independent Data Monitoring Committee (IDMC) and did not reach the clinical endpoint in the pre-specified interim analysis
In addition to ALS, Ultomiris is approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD) indications with a very high probability of expansion.
Piper Sandler analyst Christopher Raymond stated in a report in February that in 2025, Alexion's global sales revenue on MG indications may reach US$3.
